Detalhe da pesquisa
1.
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity.
Proc Natl Acad Sci U S A
; 120(3): e2207291120, 2023 01 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36634138
2.
Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents.
Clin Immunol
; 248: 109265, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36796471
3.
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO.
Br J Clin Pharmacol
; 87(6): 2511-2520, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33202059
4.
Identification of an IL-22-Dependent Gene Signature as a Pharmacodynamic Biomarker.
Int J Mol Sci
; 22(15)2021 Jul 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34360971
5.
Discovery and Qualification of Candidate Urinary Biomarkers of Disease Activity in Lupus Nephritis.
J Proteome Res
; 18(3): 1264-1277, 2019 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30525646
6.
A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function.
Mol Cell
; 33(1): 43-52, 2009 Jan 16.
Artigo
Inglês
| MEDLINE | ID: mdl-19150426
7.
Adaptive and Innate Immunity Are Key Drivers of Age at Onset of Multiple Sclerosis.
Neurol Genet
; 10(3): e200159, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38817245
8.
Systems Analysis of Immune Changes after B-cell Depletion in Autoimmune Multiple Sclerosis.
bioRxiv
; 2024 Feb 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38370778
9.
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
JAMA Neurol
; 2024 Mar 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38466277
10.
Small-molecule inducer of ß cell proliferation identified by high-throughput screening.
J Am Chem Soc
; 135(5): 1669-72, 2013 Feb 06.
Artigo
Inglês
| MEDLINE | ID: mdl-23330637
11.
Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.
Neurol Neuroimmunol Neuroinflamm
; 10(4)2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37094998
12.
Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials.
Sci Rep
; 13(1): 14313, 2023 08 31.
Artigo
Inglês
| MEDLINE | ID: mdl-37652990
13.
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
EBioMedicine
; 93: 104662, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37354600
14.
Development of an age-adjusted model for blood neurofilament light chain.
Ann Clin Transl Neurol
; 9(4): 444-453, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35229997
15.
Where CD4+CD25+ T reg cells impinge on autoimmune diabetes.
J Exp Med
; 202(10): 1387-97, 2005 Nov 21.
Artigo
Inglês
| MEDLINE | ID: mdl-16301745
16.
CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion.
J Exp Med
; 199(11): 1479-89, 2004 Jun 07.
Artigo
Inglês
| MEDLINE | ID: mdl-15184501
17.
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Neurology
; 95(14): e1999-e2008, 2020 10 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32727835
18.
Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.
Bioanalysis
; 11(15): 1405-1418, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-31401845
19.
Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL-22Fc): A Potential Therapy for Epithelial Injury.
Clin Pharmacol Ther
; 105(1): 177-189, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29952004
20.
IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis.
J Neuroimmunol
; 332: 147-154, 2019 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31034962